Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)

Tipranks - Tipranks - Thu Apr 16, 7:35AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbCellera Biologics (ABCL), Telix Pharmaceuticals (TLPPF) and Johnson & Johnson (JNJ) with bullish sentiments.

Claim 30% Off TipRanks

AbCellera Biologics (ABCL)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on AbCellera Biologics today. The company’s shares closed last Tuesday at $3.76.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 17.0% and a 55.8% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Madrigal Pharmaceuticals, and Protagonist Therapeutics. ;'>

Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $8.33, implying a 120.4% upside from current levels. In a report issued on April 9, JonesTrading also initiated coverage with a Buy rating on the stock with a $11.00 price target.

See today’s best-performing stocks on TipRanks >>

Telix Pharmaceuticals (TLPPF)

In a report released today, David Stanton from Jefferies maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$27.40. The company’s shares closed last Tuesday at $10.57, close to its 52-week low of $8.14.

According to TipRanks.com, Stanton is a 4-star analyst with an average return of 15.0% and a 45.0% success rate. Stanton covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Mesoblast Limited, and Immutep Ltd. ;'>

Currently, the analyst consensus on Telix Pharmaceuticals is a Strong Buy with an average price target of $17.72, representing a 59.6% upside. In a report issued on April 7, Bell Potter also maintained a Buy rating on the stock with a A$19.00 price target.

Johnson & Johnson (JNJ)

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Johnson & Johnson yesterday and set a price target of $265.00. The company’s shares closed last Tuesday at $240.10.

According to TipRanks.com, Chadha is a 2-star analyst with an average return of 0.0% and a 45.2% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Tandem Diabetes Care. ;'>

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $262.27, an 11.6% upside from current levels. In a report issued on April 2, Erste Group also maintained a Buy rating on the stock.

Read More on ABCL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).